CClinicalTrials.gg
RecruitingNCT07613645Updated Jul 8, 2026

Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)

An interventional study of Health counseling sessions and Diet (control diet) in Clostridioides Difficile Infection, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by University of Michigan · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling. Counseling visits will be by phone or online videoconference (e.g. Zoom). Meals will be provided for two weeks and then participants will be asked to continue similar meals for 6 more weeks.

Participants will provide responses to questionnaires and multiple stool samples over the course of the study. The goal is to understand how different health factors might impact the risk of becoming infected again with C. difficile in the future.

Of note, this study will conceal the intervention details (type of diets) so that the control group does not increase their intake with the particular diet during the study. Participants in the control arm will be unblinded at the end of the study during a debrief with a member of the study team. At that time participants will be informed of diet being tested.

02

Conditions studied

  • Clostridioides Difficile Infection

Keywords

  • Diet
  • Health counseling
  • Surveys
  • Stool samples
03

In context

Clostridium Infections

310 studies on the registry are indexed under Clostridium Infections; 50 are open to participants now.

This study's planned enrollment of 20 is below the median of 65 across 233 interventional studies indexed under Clostridium Infections.

Browse Clostridium Infections studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,475 studies on the registry; 196 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 128 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Non-recurrent non-fulminant CDI (laboratory-confirmed C. difficile infection without prior C. difficile infection within 3 months and no shock, hypotension, ileus, or megacolon)
  • Currently receiving treatment or with plan to initiate treatment for CDI
  • CDI treatment with standard regimen (fidaxomicin 200milligrams (mg) by mouth (PO) twice a day x 10-14 days or vancomycin 125mg PO 4 x a day (QID) x 10-14 days)
  • No prior advanced therapy for C. difficile (i.e. prolonged antibiotic therapy, bezlotoxumab, fecal transplant, other microbial therapy)

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy, immunotherapy, or transplant within 12 months
  • Colon not in continuity (i.e. status post total colectomy or with current ileostomy)
  • Medical comorbidities requiring specific fluid, sodium, or protein intake level outside range of prepared diet options
  • Baseline diet with > 11grams fiber/1000 kilocalories
  • Low sodium diet, vegan diet, gluten-free diet, Kosher diet or any other diet not able to be accommodated by the metabolic kitchen
  • Allergies, food preferences, or other restrictions not able to be accommodated by the metabolic (note: lactose intolerance will not impact eligibility)
  • Unwilling to stop probiotic supplements during the study period
  • Current antibiotic therapy that will continue after CDI treatment has finished
  • Hospitalized or in skilled nursing facility at time of CDI treatment conclusion
  • Pregnancy or breast-feeding
  • Unable to provide a stool sample of appropriate quality for further analysis (i.e. low volume, adulterated, delayed return, etc.)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental Diet plus health counseling

    As stated earlier, the diet and intervention details will not be listed for concealment purposes.

    Other: Diet (experimental diet)

  • Other
    Diet (control diet per protocol) plus health counseling

    As stated earlier, the diet and intervention details will not be listed for concealment purposes.

    Other: Health counseling sessions · Other: Diet (control diet)

Interventions

  • OtherHealth counseling sessions

    Participant will have two health counseling visits with a member of the study team between weeks 2-8.

  • OtherDiet (control diet)

    Participants will receive 2 weeks of prepared meals. Participants will then be asked to follow a similar diet for 6 weeks.

  • OtherDiet (experimental diet)

    Participants will receive 2 weeks of prepared meals. Participants will then be asked to follow a similar diet for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline to week 2 in alpha-diversity of fecal microbiome by 16S rRNA sequencing

    Change from baseline to week 2 (post feeding period) in alpha-diversity of fecal microbiome by 16S rRNA sequencing using Shannon index.

    Time frame: Baseline, 2 weeks (post feeding period)

Secondary outcomes

  1. Change from baseline to week 8 in microbiome alpha-diversity (Shannon Index via 16S rRNA)

    Measured by Shannon Index via 16S rRNA.

    Time frame: baseline to week 8

  2. Incidence of recurrent CDI

    Laboratory-confirmed symptomatic infection requiring treatment.

    Time frame: baseline to week 8

  3. Change in CDI-related Quality of Life (QOL) baseline to Week 8

    Patient-reported health-related quality of life assessed using the Clostridioides difficile Quality of Life Survey (Cdiff32) total score (range 0-100; higher scores indicate better quality of life).

    Time frame: Baseline to Week 8

  4. Tolerability of diet based on the mean percent of meals consumed during the first 2 weeks

    This is during the 2-weeks of receiving provided meals.

    Time frame: 2 weeks (during the provided meal period)

07

Study locations

1 of 1 sites recruiting
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    • Kira Newman, MD, PhD · Contact · kinewman@med.umich.edu · 734-615-4628
    • Kira Newman, MD, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07613645
Lead sponsor
University of Michigan
Collaborators
Michigan Nutrition Obesity Research Center
Responsible party
Kira Newman (Assistant Professor of Internal Medicine, University of Michigan) — Principal investigator
First posted
May 29, 2026
Start date
Jun 5, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Kira Newman, MD, PhD
Contact
kinewman@med.umich.edu
734-615-4628
Kira Newman, MD, PhD
principal investigator · University of Michigan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion